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Interleukin-19 (IL-19) is a recently discovered member of the IL-10 family of Class II 
cytokines.  Although it is known to be secreted by monocytes and has been associated 
with various models of disease, the biological function of IL-19 remains largely 
unknown.  IL-19 does share many important characteristics with IL-10.  Because of 
this, we hypothesized that IL-19 may be regulated in a manner similar to IL-10, and 
may provide insight into the molecular mechanism of IL-10 regulation.  In addition, 
IL-19 has been reported to increase IL-10 production in monocytes, and we theorized 
that it may be able to do the same in macrophages.  Like IL-10, IL-19 is expressed in 
regulatory macrophages.  Also, IL-19 is itself able to increase IL-10 productin in 
regulatory macrophages, and the mechanism is independent of ERK phosphorylation.  
This work suggests that IL-19 can play a central role in the anti-inflammatory 
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Chapter 1: Introduction 
The immune system 
Immunology is the study of the methods by which an organism gets rid of 
foreign or otherwise unwanted material from the body.  The immune system has the 
remarkable ability to recognize and destroy any substance found within the body that 
is identified as being foreign, or “non-self”.  The failure of the immune system to 
function properly can result in any number of diseases or disorders, ranging from 
common illnesses to serious autoimmune disorders, or even cancer.  The immune 
system itself consists of two main components; innate and adaptive immunity.  In ate
immunity provides the body’s first line of defense against invading pathogens.  It 
consists of not only physical barriers, such as the epithelia and mucosal linings of the 
gut and airways, but also phagocytic cells like neutrophils and macrophages (Mφs), 
and cytotoxic effector cells such as natural killer (NK) cells.  There are also soluble 
chemical components, such as complement and cytokines.  Innate immunity identifies 
pathogens with a relatively limited specificity.  It does this by identifyi g general 
patterns on the surface of invading organisms via pattern recognition receptors.  The 
adaptive immune response, however, exhibits a rather high level of specificity, and 
generally develops after an innate immune response.  In fact, the innate system must 
activate the adaptive system through antigen presentation and co-stimulation.  The 
adaptive immune system is composed of B and T lymphocytes (and their products) 
which identify and respond to each pathogen separately.  Each naïve lymphocyte is 




high level of specificity to a wide range of possible pathogens.  B cells produce 
immunoglobulins (Ig), also known as antibodies, to neutralize and eliminate 
extracellular microbes.  T cells mature and differentiate into two major groups; CD4+ 
and CD8+.  Naïve CD4+ T helper (Th) cells can differentiate into one of several 
types of T effector cells (Th1, Th2, TH17, etc) depending on the influence of 
cytokines secreted from innate immune cells.  Put simply, Th1 cells produce 
interferon-γ (IFN-γ) and interleukin-12 (IL-12) to promote cell-mediated immunity, 
whereas Th2 cells produce interleukin-4 (IL-4), which induces class-switching of Ig 
genes in B cells and promotes humoral (antibody-mediated) immunity.  Th17 cells 
produce IL-17, IL-17F, and IL-22.  These cells promote both neutrophilia and 
production of antimicrobial proteins as well as tissue remodeling and repair.  CD8+ 
cytotoxic T cells can recognize and destroy host cells that are infected with 
intracellular microorganisms (e.g. viruses, some species of bacteria, etc.) by lysing 
the infected cells. 
States of  macrophage activation 
Mφs play a central role in both the innate and adaptive immune responses. 
They are derived from monocytes, but are strongly influenced by their tissue
microenvironment to produce distinct subpopulations that are heterogeneous in both 
their phenotype and function1.  The classically activated Mφ is defined as a Mφ 
activated in response to stimulation with IFN-γ and/or LPS.  Once activated, it 
becomes an antigen presenting cell (APC) due to induced expression of surface 
molecules like major histocompatibility complex (MHC) class II and B7.  Classically 




amounts of the inflammatory cytokines IL-12 and IL-23, which in turn induce naïve 
CD4+ Th cells to differentiate into Th1 effector cells.  However, it is important to 
note that excessive or uncontrolled inflammation caused by classically activated Mφs 
can lead to injury to the host (e.g. tissue damage, autoimmune disease, granuloma 
formation, etc.). 
The alternatively activated Mφs are activated by either IL-4 and/or 
interleukin-13 (IL-13), and are involved in tissue repair processes.  These cells are not 
good at antigen presentation, and are also ineffective at killing microbes since they do 
not produce NO. 
The regulatory Mφs are a third distinct population of macrophages that differ 
from the other two in several ways.  The first distinguishing characteristic of these 
cells is their ability to induce Th2 effector immune responses.  The second is the fact 
that two distinct signals are necessary for their activation; (1) a stimula ory signal 
through any of the toll-like receptors (TLRs), CD40, or CD44, and (2) cross-linkage 
of Fcγ receptors (FcγR), which is accomplished by the binding of these receptors to 
antigens that have been opsonized with IgG.  These cells are able to produce large 
amounts of the anti-inflammatory cytokine interleukin-10 (IL-10), while also 
exhibiting a diminished capacity to produce the pro-inflammatory cytokine IL-12.  
Note that classically activated Mφs exhibit the exact opposite phenotype with respect 
to these two cytokines; they produce high levels of IL-12 and little IL-10.  However, 
like classically activated Mφs, regulatory Mφs produce high levels of MHC class II 
and B7 and therefore are effective APCs.  Although they can make NO, the high 




IFN-γ and effectively making reactive nitrogen species.  Both classically and 
regulatory Mφs can function as APCs, but they influence Th cell differentiation 
differently.  IL-12 produced by classically activated Mφs stimulates T cells to 
primarily produce IFN-γ in response to antigen, whereas IL-10 secreted by regulatory 
Mφs causes T cells to produce IL-4, which in turn induces B cells to produce IgG1 
against that antigen2.  Although both classically activated and regulatory Mφs express 
high levels of CD86 and exhibit low arginase activity, regulatory Mφs can also 
potentially be identified in tissue by two markers, namely sphingosine kinase-1 nd 
LIGHT3. 
IL-10 vs. IL-12 
As previously mentioned, IL-12 and IL-10 are two important cytokines with 
opposing roles in maintaining homeostasis of the immune system.  IL-12 is primarily 
produced by APCs, and most often induces an inflammatory cell-mediated immune 
response.  IL-10, however, is an anti-inflammatory cytokine.  IL-12 is transcribed and 
translated as two different subunits called p40 and p35.  Most of the biological 
activity of IL-12 occurs when these two subunits are linked, via disulfide bonding, 
into a heterodimer called IL-12p70.  IL-12 stimulates T cells and NK cells to produce 
IFN-γ, which in turn activates Mφs.  These activated Mφs are then able to increase 
their production of inflammatory cytokines, including IL-12, which results in an 
escalating feedback loop of inflammation.  These Mφs that have been activated by IL-





IL-10 is produced by macrophages, as well as Th2 cells, Treg cells, and B 
cells.  IL-10 is produced as a non-covalent homodimer with a molecular weight of 37 
kDa.  Originally identified as an inhibitory factor for cytokine synthesis 4, IL-10 can 
inhibit the transcription and translation of inflammatory cytokines by Th1 cells by 
directly acting on APCs, inhibiting the expression of costimulatory molecules like 
MHC class II and B7 as well as other cytokines needed for optimal T cell activation 5, 
6.  Since IL-10 reduces antigen presentation by APCs, it biases T cells towards a Th2 
response 7.  IL-10’s role as an anti-inflammatory cytokine is critical in maintaiing 
the delicate balance between a normal immune response intended to eliminate a 
pathogen from a host, and damage caused by excessive inflammation 8, 9.  For 
example, IL-10 has been shown to rescue BALB/c mice from lipopolysaccharide 
(LPS)-induced endotoxemia 2, 10.  IL-10 can also upregulate the expression of FcγRs 
on Mφs, which is correlated with enhanced phagocytosis of opsonized particles 11.  
Toll-like receptors 
One of the basic strategies that the innate immune system uses to fight 
infection is to identify certain molecular structures, called “pathogen-associ ted 
molecular patterns” (PAMPs) that are common to infectious organisms.  PAMPs are 
loosely defined as highly conserved microbial components that have distinct features 
that are not associated with host molecules (e.g. bacterial LPS, CpG DNA, flagellin, 
etc.).  The innate immune system has the ability to recognize and respond to PAMPs 
through the use of certain germline-encoded signaling receptors and, by activating 
downstream intracellular signaling pathways, can initiate and control the major




pattern recognition receptors, including a family of receptors that were first identified 
in fruit flies known as the Toll-like receptors (TLRs) which are also expressed on 
dendritic cells, B cells, and even on non-immune cells such as epithelial cells.  TLR  
play an important role in innate immunity, as well as in the development of an 
adaptive immune response.  Activation of TLRs leads to signal transduction cascades 
that cause cells to produce inflammatory cytokines and transcribe antimicrobial 
genes.  It also induces the upregulation of co-stimulatory molecules that in turn
induce an adaptive immune response.  To date, there have been 11 TLRs identified in 
humans and 13 in mice, although the function of some of these TLRs are not fully 
understood 12.  What distinguishes TLRs from other receptors is a conserved 
extracellular region consisting of several tandem leucine-rich repeat motifs, and a 
cytoplasmic tail consisting of a sequence that is homologous to the interleukin 1 
receptor (IL-1R) domain, known as the Toll/IL-1R homology (TIR) domain.  TIR 
domains are crucial to TLR functioning since they bind to adaptor molecules that 
mediate the downstream TLR signaling pathways.  These activating adaptors include 
myeloid differentiation primary response gene 88 (MyD88), TIR domain-containi g 
adaptor protein (TIRAP), TIR domain-containing adaptor inducing IFN-β (TRIF), 
TRIF-related adaptor molecule (TRAM), and others 13.  Most of the TLRs are 
expressed on the cell surface, while TLR’s 3, 7, 8, and 9 are found almost exclusively 
inside intracellular compartments such as endosomes.  MyD88 is the key adaptor 
protein in almost all of the TLR signaling pathways except for TLR3, and is required 
for innate immune responses to a variety of pathogenic organisms, as evidenced by 




recognized by a specific TLR, there is actually a great deal of diversity as to which 
ligands a given TLR can recognize15.  TLR2, for instance, will not only bind 
peptidoglycan (found on Gram positive bacteria), but also other structurally unrelated 
molecules like LAM (Mycobacteria), hemagglutinin (Measles virus), and 
phospholipomannan (Candida).  Genetically engineered mice that are deficient in a 
given TLR will easily succumb to infection by the organisms that the TLR recognizes 
in normal mice.  Hence, TLR2 -/- mice are more susceptible than wild-type mice to 
infection by any Gram positive bacteria of the family Streptococcus or 
Staphylococcus 16. 
Fcγ receptors 
Antibody-mediated, or humoral, immune responses also play a critical role in 
both innate and adaptive immunity.  One method by which antibodies regulate 
immune responses is through interactions with Fc receptors.  IgG antibodies 
specifically interact with the Fc (gamma) receptor (FcγR), which is expressed on 
various immune cells, and plays a central role in phagocytosis, immune complex 
clearance, and cytokine production 17. The FcγR recognizes and binds to opsonized 
particles coated with IgG, which allows the Mφ to ingest and destroy pathogens.  
Structurally, the FcγR is composed of an α chain that binds to the Fc portion of IgG, 
and a γ chain dimer that is associated with signal transduction. There are four known 
types of Fc-receptors; FcγRI, FcγRII, FcγRIII, and FcγRIV, which can be further 
classified as either inhibitory (FcγRIIB) or activating (all other FcγRs) receptors.  




and FcγRIV have about a 100-1000 fold lower affinity for monomeric IgG 18.  FcγRII 
and FcγRIII, however, are capable of binding IgG immune complexes 19.  Of the 
activating FcγRs (with the exception of human FcγRIIa and FcγRIIC), all activating 
FcγRs contain an immunoreceptor tyrosine-based activating motif (ITAM) in their 
cytoplasmic domain.  The FcγRIIB, on the other hand, contains an immunoreceptor 
tyrosine-based inhibitory motif (ITIM), and indeed activation of inhibitory FcγRIIB 
serves to negatively regulate activation of the other FcγRs 19. 
Cross-linking of FcγRs by immune complexes leads to the phosphorylation of 
the ITAMs of the γ-chain by Src family kinases.  This in turn leads directly to the 
recruitment and activation of the tyrosine kinase Syk.  Syk contains two N-terminal 
Src homology 2 (SH2) domains and a C-terminal kinase domain with a flexible linker 
between them.  Syk is activated in a three-fold process; binding of its SH2 domain to 
the phosphorylated ITAMs of the FcγR γ chain, phosphorylation by Src family 
kinases, and finally autophosphorylation 20. Once activated, Syk can then induce 
various signal transduction molecules including phosphoinositide 3-kinase (PI3K), 
and regulators of Ras and other G proteins.  This leads to activation of mitogen-
activated protein kinases (MAPKs) such as p38 and ERK, and calcium-dependent 
signaling pathways 18.  In Mφs, IL-10 production is dependent on signaling mediated 
through the γ chain of FcγR following cross-linking and activation of this receptor 21. 
Mitogen-activated protein kinase (MAPK) signaling pathways 
MAPK signaling pathways are essential in a variety of cellular processes, 




response.  Unsurprisingly, they are very highly evolutionarily conserved in 
eukaryotes, from yeast all the way to humans.  Currently, there are four preeminent 
MAPK pathways identified in mammals; the extracellular signal-regulated kinase 1 
and 2 (ERK1/2) pathway, the p38 pathway, the c-Jun NH2-terminal kinase (JNK) 
pathway, and the ERK3, 4, and 5 pathway.  The key feature of the MAPKs is that 
activation requires phosphorylation at both a threonine and a tyrosine residue in a 
conserved Thr-X-Tyr (TXY) motif.  This type of phosphorylation is much longer-
lived than the tyrosine phosphorylation associated with FcγRs and other membrane-
bound receptors, which allows the MAPKs to convert these short signals into 
sustained ones that can be relayed downstream to the nucleus and can alter the pattern 
of gene expression.  The protein kinase that catalyzes phosphorylation of the TXY 
motif is called a MAP kinase kinase (MKK), which in turn is activated through 
phosphorylation of their Ser/Thr residues by a MAP kinase kinase kinase (MKKK).  
Activation of all MAPKs is achieved via this kind of triple kinase cascade; MKKK to 
MKK to MAPK 22. 
 ERK 1 and 2 are ubiquitously expressed in all cell types, and are involved in 
cell growth and differentiation.  Typically, the ERK 1/2 pathway is activated by 
receptor tyrosine kinases and G protein-coupled receptors that transmit signals to the 
Raf/MEK/ERK cascade.  Briefly, the GTP-binding protein Ras is activated via 
signaling from a membrane receptor responding to the presence of growth factors,
carcinogens, or transforming agents.  This allows Ras to interact with and activate 
Raf, although the exact mechanism is not well understood 23.  Activated Raf can then 




conserved Thr-Glu-Tyr (TEY) motif 24.  Once it has been phosphorylated, ERK 1/2 
accumulates in the nucleus, where it is known to interact with several nuclear proteins 
like NF-AT, c-Fos, c-Myc, and STAT3, as well as the nuclear proteins MSKs, 
MNKs, and RSKs 24.   
 The p38 pathway is heavily influenced by inflammatory cytokines (e.g. IL-1, 
TNF-α, etc.) and environmental or physical stresses (e.g. oxidative stress, UV 
radiation, etc.).  There are several MKKKs in this pathway, including MEKK’s 1 
through 4, MLK2 and 3, and Tpl2, among others.  The MKK’s MEK3 and MEK6 are 
also in this pathway, as are the four known isoforms of p38 (α, β, γ, and δ). p38γ is 
found in skeletal muscle, and p38δ is expressed in lung, kidneys, and the small 
intestine. However, p38α and β are ubiquitously expressed in all cell types.  MEK3 
and 6 show a high degree of specificity for p38, and will not activate ERK1/2 or JNK.  
Specifically, activation of p38 by MEK3/6 is accomplished by phosphorylation of a 
conserved Thr-Gly-Tyr (TGY) motif in the activation loop of p38.  Once activated, 
p38 can translocate from the cytoplasm to the nucleus and activate transcription 
factors such as ATF 1/2, NF-κB, and p53 25. 
 It is well established that the JNK pathway is activated in response to 
cytokines, but it is also activated by environmental stresses like UV radiation and 
growth factor deprivation.  In fact, the JNK pathway was first identified n studies 
where rat liver cells were injected with the protein synthesis inhibitor cyclohexamide 
26.  Regulation of the JNK pathway is extremely complex, involving over 13 MKKKs.  
Like p38 and ERK1/2, JNK activation requires dual phosphorylation on a conserved 




activation allows it to translocate to the nucleus following stimulation.  The most 
well-known substrate for JNK is the transcription factor c-Jun, which is part of the 
AP-1 transcription complex that controls the expression of many cytokine genes 27. 
 MAPKs are central mediators of gene expression in eukaryotes in response to 
extracellular signals, including cytokine stimulation.  As previously mentioned, 
MAPKs can easily phosphorylate transcription factors, but they can also activate o-
regulatory proteins and are involved in chromatin remodeling.  Thus, MAPKs can 
influence protein stability, localization, and transcription, as well as DNA binding and 
nucleosome accessibility 28, 29. 
Regulation of IL-10 
 Expression of IL-10 is regulated at the level of gene transcription 30, mRNA 
stability 31, and via chromatin remodeling at the IL-10 locus 32.  Numerous 
transcription factor binding sites are known to exist within the IL-10 promoter region, 
and are associated with IL-10 regulation in Mφs.  For example, the specificity binding 
protein 1 (Sp1) binding site in the murine IL-10 promoter (-89/-78) is a central 
mediator for IL-10 production, and is necessary for LPS-induced IL-10 synthesis 33.  
Although Sp1 is known to be activated via phosphorylation by Sp1 kinase, it has been 
shown in human Mφs that Sp1 phosphorylation is dependent on p38 MAPK 34.   
Signal transducer and activator of transcription-3 (STAT3) also binds to the IL-10 
promoter at two sites (-629/-621 and -479/-471), and in fact IL-10 can induce its own 
expression in an autocrine function via activation of STAT3 35.  However, numerous 
studies in STAT3 conditional knockout mice have shown that, while STAT3 clearly 




studies in mice have also shown that the NF-κB family member p50 forms 
homodimers and binds to a site (-130/-100, -124/-103) in the IL-10 promoter 37. 
 In addition to transcription factor mediated-regulation, IL-10 is also regulated 
by epigenetic modifications to the promoter site.  In Mφs, transcription factor binding 
is actually preceded by a transient phosphorylation of chromatin around the IL-10 
promoter, which is dependent on ERK activity 32, 38.  This evidence therefore provides 
a mechanistic explanation for the fact that optimal IL-10 production seen in the 
activated regulatory Mφs upon stimulation with two distinct signals; a TLR ligand 
(LPS) and immune complexes.  As with most cytokines, the signal provided by TLR 
activation induces transcription factor activity within the nucleus.  However, in the 
case of IL-10, this signal is not sufficient to activate transcription of the il-10 gene 
because the promoter site itself remains physically inaccessible.  The second signal, 
provided by cross-linking of the FcγRs by immune complexes, activates the tyrosine 
kinase Syk.  This, in turn, activates ERK which then phosphorylates histone H3 
associated with the IL-10 promoter.  This modification of the histone is rapid and 
transient, peaking only 30 minutes post activation after which histone 
phosphorylation rapidly declines 32, 38.   
IL-19 and the IL-10 family of cytokines 
 A number of Class II cytokines with sequence homology to IL-10 have been 
discovered either by data mining of EST databases, or by other means and were later 
found to be IL-10 homologues 30.  The IL-10 family now consists of six members; IL-
10, IL-19, IL-20, IL-22, IL-24 (MDA-7), and IL-26.  The genes for IL-19, IL-20, and 




gene for IL-19 is closest in proximity to IL-10, although the two genes run antisense 
with respect to each other.  Like IL-10, the gene for IL-19 has five exons and four 
introns, and the length of each exon is virtually identical to the respective exons of 
IL-10 39.  IL-19 has a putative molecular weight of ~21 kDa, although there are two 
glycosylation sites on the protein that could explain some reports of multiple IL-19 
bands in the 35-40 kDa range in SDS-PAGE analysis 30.  The crystal structure of IL-
19 has been solved.  Although there is only ~20% sequence homology with IL-10, IL-
19 does share a very similar three-dimensional structure to IL-10, the main 
differences being that 1) IL-19 has six α-helices whereas IL-10 has seven, 2) IL-19 
exists as a monomer and IL-10 as a dimer, and 3) the N-terminal region of both 
cytokines differ dramatically 40. 
Each of the IL-10 family members binds to one or more of the Class II 
cytokine receptors (Fig. 1), with some receptor subunits being present in more than 
one receptor, suggesting an overlap in function 41, 42.  There is also commonality in 
the downstream signaling of these cytokines, since all of the Class II cytokine 
receptors activate Janus kinase (JAK) and/or STAT signaling pathways 43.  IL-19 in 
particular binds to the IL-20R1/IL-20R2 receptor complex and activates STAT3, as 
do IL-20 and IL-22 41, 44.  It is therefore likely that the biological function of IL-19, as 
with all the IL-10 family members, is largely dependent on the cells secreting and 
responding to it, as well as the microenvironment in which it is released 43. 
IL-19 is known to be secreted by monocytes, and to a lesser extent, by B cells 
45.  LPS stimulation of monocytes induces IL-19 expression after 4hr, compared with 




significant increase in LPS-induced IL-19 mRNA expression, but inflammatory 
cytokines such as IFN-γ and TNF-α do not have this affect.  Monocytes treated with 
IL-19 release IL-6 and TNF-α, as well as reactive oxygen species.  In addition, IL-19 
can induce apoptosis 46. 
 
Fig.1. The IL-10 family of cytokine receptors.   
IL-10 family members all bind to structurally related receptors, some of which s are 
receptor subunits and some of which bind to more than one cytokine.  All members of 
this family signal through STAT and JAK kinase pathways. 
 
Since IL-19 can bind to the IL-20 receptor complex, it is involved in the 
pathogenesis of certain chronic inflammatory diseases, like psoriasis and asthma.  It is 
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Treatment with IL-4 can induce Th2 differentiation in naïve and memory T cells,
suppressing IFN-γ production and alleviating psoriasis.  Studies have shown that this 
kind of treatment has no effect on levels of IL-20 or its receptor, but it significa tly 
reduces the amount of IL-19 mRNA 47.  IL-19 is also known to be elevated in the 
serum of asthma patients in both human and mouse models 48.  It can not only induce 
the production of Th2-associated cytokines like IL-10, IL-4, and IL-13 (and even 
itself in an autocrine fashion 49) in multiple cell types, but can also bias T cell 
development towards a Th2 response 50. 
Although the human IL-19 promoter has been cloned 46, the mouse IL-19 
promoter has not, and it is not yet known what transcription factors are necessary for 
IL-19 production in either model.  The purpose of this study is to determine whether 
IL-19 is expressed by regulatory Mφs, and if so what similarities and/or differences 




Chapter 2: Materials and Methods 
Mice 
 BALB/c mice were purchased from Taconic Farms (Germantown, NY).  IL-
10-/- mice were purchased from Jackson Laboratory (Bar Harbor, Maine).  All mice 
were used at 6-10 weeks of age as a source of bone marrow-derived macrophages 
(BMM φs).  Mice were maintained in HEPA-filtered Thoren units (Thoren Caging 
Systems, Hazelton, PA) at the University of Maryland (College Park, MD).  All 
procedures using animals were reviewed and approved by the University of Maryland 
Institutional Animal Care and Use Committee. 
Cell culture 
 BMMφs were prepared by removing the tibias and femurs of 6-10 week old 
mice and flushing the bone marrow out with PBS + penicillin/streptomycin.  The 
cells were plated in Petri dishes in DMEM/F12 (Fisher Scientific, Pittsburgh, PA) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, 
UT), 2 mM glutamine (Fisher Scientific), 100 U/mL penicillin (Fisher Scientific), 100 
µg/mL streptomycin (Fisher Scientific), and 10% L929 conditioned medium obtained 
from the supernatants of M-CSF secreting L929 (LC14) fibroblasts.  The cells were 
fed on day 2, and complete medium was replaced on day 6.  All BMMφs were used at 
7-10 days for experiments.  BMMφs were removed from the Petri dishes using 
Cellstripper (Mediatech, Manassas, VA) and were plated onto 48-well plates for 




Western blotting (2x106 Mφs/well).  All cells were cultured overnight in complete 
medium without L929 before experimentation. 
 RAW264.7 macrophages were obtained from the American Type Culture 
Collection (Manassas, VA), and were grown in RPMI (Fisher Scientific) 
supplemented with 10% FBS, 2 mM glutamine, 100 µg/mL streptomycin, and 100 
U/mL penicillin.  Cells were plated at 2x105 cells per well of a 48-well plate for 
transient transfections and luciferase assays. 
Macrophage activation 
Either BMMφs or RAW264.7 cells were used in all experiments. Cells were 
grown and plated as described above, then washed and stimulated with 10 ng/mL of 
Ultra-Pure LPS (Escherichia coli K12, Invivogen, San Diego, CA), or with LPS plus 
immune complexes consisting of IgG-opsonized ovalbumin (OVA).  Immune 
complexes were made by mixing a tenfold molar excess of rabbit anti-OVA IgG 
antibody (Cappel, Durham, NC) to OVA (Worthington, Lakewood, NJ) for 30 min at 
room temperature.  Where indicated, cells were washed and primed overnight with 
either 100 U/mL recombinant IFN-γ or 10 U/mL recombinant IL-4 (R&D Systems, 
Minneapolis, MN) before being washed and stimulated.  Some experiments also 
involved priming with recombinant IL-19 (Biosource International Inc., Camarillo, 
CA) at the indicated concentrations and for the indicated time periods, before cells 
were stimulated.  Where indicated, the ERK inhibitor U0126 (5 µM) or the p38 





 Cells were stimulated overnight as described above.  Supernatants were 
collected, and cytokine concentrations were measured by sandwich ELISA using the 
following pairs of capture and detection (biotinylated) antibodies (BD Pharmingen, 
San Jose, CA); IL-10, JES5-2A5 and JES5-16E3; IL-12/23p40, C15.6 and C17.8; 
TNF-α, G281-2626 and MP6-XT3.  Antibody concentrations used were according to 
the manufacturer’s instructions.  Cytokine concentrations were compared to a 
standard curve (4000-0 pg/mL) generated by serial dilution of recombinant protein 
standards (BD Pharmingen).  Streptavidin alkaline phosphatase (AP) and p-
nitrophenyl phosphate (PNPP) substrate (Southern Biotechnology, Birmingham, AL) 
were used to develop samples according to the manufacture’s instructions.  All 
samples were placed in 96-well flat bottom plates, and measured at 405 nm. 
RT-PCR and quantitative real-time PCR 
 RNA was extracted from BMMφs using TRIzol reagent (Invitrogen Life 
Technologies, Carlsbad, CA).  Any contaminating DNA was removed via treatment 
with DNase I.  RNA concentrations were quantified using spectrophotometry.  cDNA
was generated from total RNA using the ThermoScript RT-PCR system (Invitrogen 
Life Technologies) with oligo(dT)20 primers as per the manufacturer’s instructions.  
Standard PCR analysis was performed using Platinum PCR Supermix (Invitrogen 
Life Technologies).  Electrophoresis of the final PCR products was performed after 
amplification to ensure that a single product had been obtained.  Real-time PCR 
analysis was conducted on the Roche LightCycler 480 Real-Time PCR System using 




manufacturers instructions.  The CT value for GAPDH was used to normalize 
variations in loading amount.  A ∆∆CT value was obtained by subtracting control ∆CT 
values from the corresponding experimental ∆CT.  Data was then represented as a 
fold difference compared with the control by raising 2 to the ∆∆CT power.  The 





IL-10 NM_010548 5’-CCAGTTTTACCTGGTAGAAGTGATG-3’ 
5’-TGTCTAGGTCCTGGAGTCCAGCAGACTCAA-3’ 
IL-10 
(For Real-Time PCR) 
NM_010548 5'-AAGGACCAGCTGGACAACAT-3' 
5'-TCTCACCCAGGGAATTCAAA-3' 
IL-12/23p40 NM_008352 5’-ATGGCCATGTGGGAGCTGGAGAAAG-3’ 
5’-GTGGAGCAGCAGATGTGAGTGGCT-3’ 
IL-19 NM_001009940 5’-TCTGCTCTCTGATCCCACCT-3’ 
5’-TGCACTACAGCACACCACAA-3” 
GAPDH NM_001001303 5’-GCACTTGGCAAAATGGAGAT-3’ 
5’-CCAGCATCACCCCATTAGAT-3’ 
Table 1.  Primer pairs used in both standard and quantitative Real-Time PCR. 
Western blotting 
 BMMφs were plated at 2x106 cells/well in 6-well plates overnight as 
described above.  Cells were then lysed in ice-cold lysis buffer (100 mM Tris (pH 8), 
2 mM EDTA, 100 mM NaCl, 1% Triton X-100, and a Complete EDTA-free Protease 
Inhibitor Cocktail Tablet (Roche Diagnostics, Indianapolis, IN)), 5 mM sodium 
vanadate, 10 mM sodium fluoride, 10 mM glycerophosphate sodium, and 5 mM 
sodium pyrophosphate, and left on ice for 30 min.  Lysates were cleared by 
centrifugation (13,000 rpm, 10 min. 4oC).  Pre-cast 10% SDS-polyacrylamide gels 
(Bio-Rad) were loaded with equal amounts of protein per well, which were then 




were then incubated with primary antibodies (1/1000 in 5% BSA, TBS-Tween 20) 
overnight at 4oC.  The membranes were then washed and incubated with HRP-
conjugated secondary antibody (1/5000) for 1 hr at room temperature, and were 
developed using Lumi-Light PLUS Western Blotting Substrate (Roche Diagnostics) 
according to the manufacturer’s instructions. 
Generation of pGL4.19-IL-19 promoter plasmid 
 Approximately 3 kb of the mouse IL-19 promoter was cloned from murine 
genomic DNA by PCR using the Expand Long Template PCR System (Roche 
Diagnostics) and the following primers: forward- 5’-
GATATCTCCGCACCAAGCCTACATAGT-3’ and reverse- 5’-
TCTAAGATCTAAGGTCAGACAACCCATGCTC-3’ (Fig. 2).  The PCR product 
was ligated into the pCRII-TOPO vector (Invitrogen Life Technologies) to generate 
usable quantities.  The cloned promoter fragment (-3000/+200 relative to the 
transcriptional start site) was removed using EcoRV and BglII restriction enzymes, 
then gel purified and ligated into the pGL4.19[luc2CP/Neo] luciferase reporter vector 
(Promega Corporation, Madison, WI).  The sequence of the resulting ~3 kb promoter 
fragment was verified by GENEWIZ Inc. (Germantown, MD).  The -2000/+200 
promoter construct was made by SacI digestion of the -3000/+200 construct, while 
the -1000/+200 promoter construct was made by digestion of the -3000/+200 
construct with KpnI.  In both cases the larger fragment was then gel purified, and the 



































Fig. 2.  IL-19 promoter plasmid constructs. 
(A) Plasmid map of the 3 kb pGL4.19[luc2CP/Neo] IL-19 promoter construct used in 
the construction and validation of the 2 kb and 1 kb reporter plasmids. Relevant 
restriction enzyme sites are indicated. The 2 kb promoter construct was created by 
SacI digestion, the 1 kb construct by digestion with KpnI. Both constructs were then 
filled in with Klenow and blunt-end ligated. 
(B) Restriction enzyme analysis for validation of IL-19 promoter construct .  
Plasmids were either uncut, or cut with restriction enzymes as indicated. 
Transient transfections and luciferase assays 
 RAW264.7 cells were transiently transfected using the FuGENE HD 
transfection reagent (Roche Diagnostics).  2 µg of plasmid was added to 3 µg of 
FuGENE diluted in 100 µL of RPMI and incubated at room temperature for 30 min.  







1. 1 kb ladder
2. pGL4.19 vector
3. pGL4-IL-19 (-3 kb/+200)
4. pGL4-IL-19 (-3 kb/+200) cut with EcoRV
5. pGL4-IL-19 (-2 kb/+200)
6. pGL4-IL-19 (-2 kb/+200) cut with SacI
7. pGL4-IL-19 (-1 kb/+200)




20 µL of the resulting transfection complex was added per well of a 48-well plate.  
Each reporter construct was co-transfected with the pRL-null Reni la luciferase 
plasmid (Promega) at a ratio of 40:1 and incubated at 37oC overnight.  Media was 
replaced the following morning, and cells were stimulated as indicated in figures.  
Luciferase activity was measured using the Dual-Luciferase Reporter Assay System 
(Promega).  The firefly luciferase activity was measured for each IL-19 promoter 




Chapter 3: IL-19 Production in Regulatory Macrophages 
 The published literature on IL-19 demonstrates that this cytokine, as well as 
other IL-10 family members, shares many important characteristics with IL-10.  It has 
led many researchers to speculate that IL-10 may in fact be the evolutionary 
descendent of IL-19 and other members of the extended family51.  The similarity in 
three-dimensional structure of the two cytokines suggests that both proteins might be 
able to bind to the other’s respective receptor, suggesting an overlap in function.  The 
redundant nature of signaling within the IL-10 family of cytokine receptors is further 
evidence to support this theory.  Finally, the close proximity of the respective 
promoter sites for these two genes suggests that it is possible they share transc ip io  
factor binding sites, implying that not only do the two cytokines have similar 
functions but that they are themselves regulated in a similar manner.  Due to the 
unique role that IL-10 has in regulatory macrophages, we hypothesized that IL-19 
might have a similar role for the reasons stated above.  Furthermore, we hypothesized 
that any differences that occur between IL-19 production or activity and IL-10 might
provide further insights into the complex molecular regulatory mechanism of IL-10. 
IL-19 mRNA is upregulated in regulatory macrophages, but is negatively regulated 
by IL-10 
We first examined whether IL-19 was produced in our model of BMMφs.  
Bone marrow cells were grown in culture from 6-10 week old BALB/c mice as 
described in Materials and Methods to produce BMMφs.  Cells were stimulated either 




Where indicated, cells were also pretreated overnight with either IFN-γ or IL-4 in 
order to produce classically activated or alternatively activated macrophages 
respectively.  RNA was extracted from the cells at the designated tim points (Fig. 3, 
left side) and reverse transcribed into cDNA.  PCR analysis was then performed using 
primers specific for mature IL-19 transcript.  A basal level of IL-19 mRNA was 
expressed in LPS-stimulated macrophages after 4 hours, but a higher level ofmRNA 
was expressed in cells treated with LPS/IC.  The kinetics of mRNA expression is also 
different in LPS/IC-treated cells.  Detectable levels of IL-19 mRNA were seen as 
early as 1 hour post-stimulation.  Priming with IFN-γ did not alter either the kinetics 
or level of mRNA expression in response to any stimulation.  However, IL-4 priming 
did alter the kinetics of IL-19 expression in that IL-19 mRNA production 
dramatically tapered off by 4 hours post-stimulation with LPS/IC.  IL-19 therefore 
does share a characteristic with IL-10, namely that cytokine mRNA expression i  
upregulated and faster in regulatory macrophages as compared to cells treatd with 
LPS alone.   
It has also been reported in human monocytes that IL-19 can itself induce IL-
10 expression and that IL-10 can downregulate production of IL-1949.  To determine 
whether or not this is also the case in murine macrophages, this experiment was 
repeated using macrophages from IL-10 -/- mice (Fig. 3, right side).  IL-19 was 
basally expressed at detectable levels even without stimulation in these cells, and a 
higher overall level of mRNA was expressed in response to LPS stimulation as 
compared to wild-type cells.  The kinetics of LPS-induced IL-19 mRNA production 




























Fig. 3.  IL-19 expression in classically activated, alternatively activated, and 
regulatory macrophages. 
RT-PCR was performed to examine IL-19 expression in different populations of 
BMM φs isolated from wild-type BALB/c (left) and IL-10 -/- mice (right).  Cells were 
treated overnight either with media alone (top group), 100 U/mL IFN-γ (center group) 
or 10 U/mL IL-4 (bottom group).  RNA was collected and reverse transcribed into 
cDNA after stimulation with either LPS alone, or with LPS plus immune complexes 
(LPS/IC) for the indicated time periods.  GAPDH RNA was used as a loading control.  






stimulation.  A similar pattern was seen in response to cells primed with IFN-γ.  LPS 
stimulation of IFN-γ primed IL-10 -/- cells produced overall levels of IL-19 mRNA 
that were higher compared to wild-type cells, and mRNA transcription occurred 
earlier at 1 hour post-stimulation.  No significant difference was seen in knockout 
cells primed with IL-4 as compared to wild-type controls.  These data indicate that, as 
in monocytes, IL-10 plays a regulatory role in IL-19 production. 
Activity of IL-19 promoter in response to stimulation 
To further investigate the production of IL-19 in macrophage populations, we 
examined luciferase activity in RAW 264.7 cells that had been transfected with IL-19 
promoter constructs of various lengths.  Cells were transfected with either the full 
length promoter construct (-3 kb/+200, Fig. 2), or with truncated promoters 
(-2 kb/+200, -1 kb/+200).  RAW cells that had been transfected with either of the two 
truncated promoters showed only modest levels of luciferase activity as compared to 
the empty pGL4.19 vector under any stimulation conditions.  However, the full length 
promoter exhibited a dramatic increase in luciferase activity upon stimulation with 
LPS (Fig. 4A), indicating that the primary transcription factor binding sites are most 
likely located within the region from -3 kb to -2 kb upstream from the transcription 
start site.  LPS stimulation of the full-length promoter in classically activated cells 
(Fig 4B) exhibited an even higher level of luciferase activity, whereas altern tively 
activated cells (Fig. 4C) exhibited an activity level lower than that of classi lly 
activated cells, but still higher than unprimed cells.  Interestingly, stimulation with 
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Fig. 4.  Luciferase activity of RAW 264.7 cells transfected with either full-length or 
truncated IL-19 promoter vectors after stimulation with LPS or LPS/IC in the 
presence or absence of IFN-γ or IL-4. 
pGL4.19 luciferase reporter constructs containing either the full-length (-3 kb/+200) or 
truncated promoter constructs (-2 kb/+200, -1 kb/+200) were transfected into RAW 264.7 
cells, then grown overnight either in the presence of media alone (A), 100 U/mL IFN-γ 
(B), or 10 U/mL IL-4 (C).  Cells were then stimulated with either LPS or LPS/IC for 
8hrs.  Each sample was measured for firefly luciferase activity and normalized to Renilla 
luciferase activity (transfected at a ratio of 40:1).  Values are reprs nted as fold changes 
relative to unstimulated cells transfected with the empty vector.  Figures shown are 
representative of three independent experiments.  Error bars are ± standard devi tion for 




conditions, in contrast to what was seen in IL-19 mRNA experiments. 
Discussion 
We have shown here that IL-19 is in fact expressed in macrophages, and that 
it does indeed share many important similarities with IL-10.  Like IL-10, IL-19  
expression is upregulated in the presence of immune complexes and the classical 
activation signals IFN-γ and LPS1.   Interestingly, IL-19 expression in response to 
LPS stimulation is not enhanced by priming with IL-4. This is in stark contrast to 
what has been reported in human monocytes, where IL-19 production is upregulated 
by IL-4 and downregulated by IFN-γ39.  IL-19 has also been associated in the 
literature with various inflammatory processes (e.g. atherosclerosis, asthma48), and its 
exact role in inflammatory processes is unclear due to the fact that it is secreted at 
different time points and by different cells types depending on the model of 
inflammation being studied.  Our evidence, taken in conjunction with what has been 
reported in human monocytes, supports the idea that IL-19 production, like IL-10, is 
highly dependent on the cell type involved and the microenvironment in which the 
cell is found. 
As has been reported previously in human monocytes, IL-19 is itself inhibited 
by IL-10 production in macrophages49.  We showed that IL-19 is expressed at basal 
levels in IL-10 -/- mice even without stimulation, and that IL-19 production is 
increased in response to stimulation with LPS/IC.  Oddly, these findings did not 
correlate with studies of the IL-19 promoter, which only showed activity in response 
to stimulation with LPS.  Faced with a similar problem with regard to the IL-10 




seen in regulatory macrophages is dependent on histone modifications and chromatin 
remodeling, both of which would not have been present on the plasmid vector used in 
a luciferase assay32.  It is possible that the same is true for the IL-19 promoter.  Future 
studies using chromatin immunoprecipitation (ChIP) assays should determine 
whether histone modifications occur at distinct sites along the IL-19 promoter, and 





Chapter 4: Role of MAPKs in IL-19 expression 
Inhibition of ERK decreases IL-19 promoter activity in response to LPS stimulation 
Previous work by our lab has shown that the MAPK ERK plays a central role 
in IL-10 production in regulatory macrophages, specifically translating signals from 
cross-linked FcγRs into dynamic and transient remodeling of chromatin at the IL-10 
promoter.  This results in the superinduction of IL-10 seen in this macrophage 
population3, 32, 38.  To determine if IL-19 promoter activity might also be dependent 
on ERK, we tested whether or not IL-19 promoter constructs still exhibited luciferase 
activity in the presence of the ERK inhibitor U0126.  RAW 264.7 cells were 
transfected with the IL-19 promoter constructs as described previously.  Cells were 
then pretreated with 5 µM U0126 or vehicle alone, before being stimulated with LPS 
(Fig. 5A) or LPS/IC (Fig. 5B).  As before, only the full length 3 kb construct 
exhibited any significant luciferase activity in response to LPS stimulation.  This 
response was completely erased by the presence of U0126, bringing luciferase 
activity back down to basal levels seen in unstimulated control samples.  As before, 
none of the constructs showed any significant luciferase activity in response to 
stimulation with LPS/IC.  Interestingly, when the p38 inhibitor SB203580 was used 
instead of U0126, the luciferase activity of the full-length 3 kb promoter construct 
was inhibited by approximately half in response to LPS stimulation instead of being 
completely erased as it was with the ERK inhibitor.  Cells stimulated with LPS/IC 
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Fig. 5.  Luciferase activity of RAW 264.7 cells transfected with either full-length 
or truncated IL-19 promoter vectors after stimulation with LPS or LPS/IC in 
the presence or absence of U0126. 
pGL4.19 luciferase reporter constructs containing either the full-length (-3 kb/+200) 
or truncated promoter constructs (-2 kb/+200, -1 kb/+200) were transfected into 
RAW 264.7 cells.  Cells were pretreated with 5 µM U0126 or vehicle alone, then 
stimulated with either LPS (A) or LPS/IC (B) for 8hrs.  Each sample was measured 
for firefly luciferase activity and normalized to Renilla luciferase activity (transfected 
at a ratio of 40:1).  Values are represented as fold changes relative to unstimulated 
cells transfected with the empty vector.  Figures shown are representative of three 
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Fig. 6.  Luciferase activity of RAW 264.7 cells transfected with either full-length 
or truncated IL-19 promoter vectors after stimulation with LPS or LPS/IC in 
the presence or absence of SB203580. 
pGL4.19 luciferase reporter constructs containing either the full-length (-3 kb/+200) 
or truncated promoter constructs (-2 kb/+200, -1 kb/+200) were transfected into 
RAW 264.7 cells.  Cells were pretreated with 5 µM SB203580 or vehicle alone, then 
stimulated with either LPS (A) or LPS/IC (B) for 8hrs.  Each sample was measured 
for firefly luciferase activity and normalized to Renilla luciferase activity (transfected 
at a ration of 40:1).  Values are represented as fold changes relative to unstimulated 
cells transfected with the empty vector.  Figures shown are representative of three 





unstimulated controls.  These results are an interesting contrast to the aforementioned 
previous data obtained by our lab.  We have shown that modest amounts of 
phosphorylated ERK and p38 are produced in unprimed macrophages in response to 
LPS.  However, these levels are always moderate in comparison to those produced by 
stimulation with LPS/IC, and we have never shown any absolute requirement of 
MAPK activity to produce IL-10 in macrophages stimulated with LPS alone38.  











Chapter 5:  Regulation of IL-10 Production by IL-19 
 
Priming with IL-19 upregulates IL-10 expression in a dose-dependent manner  
 Previous data has demonstrated that, in human monocytes, IL-19 can induce 
IL-10 production, but is also negatively regulated by IL-10 in the manner of a 
negative feedback loop49.   To determine if IL-19 could increase production of IL-10 
in regulatory macrophages, we measured cytokine production by ELISA in BMMφs 
that had been primed for 6 hours with 100 pg/mL of recombinant IL-19.  IL-19 
priming did indeed cause an increase in IL-10 production in macrophages that had 
been stimulated with LPS/IC as opposed to cells treated with LPS/IC alone (Fig. 7A).  
This effect was limited to IL-10 production, since there was no statistically significant 
decrease in either IL-12/23 p40 (Fig. 7A) or TNF-α (Fig. 7B) production.   
Further analysis indicated that this effect of IL-19-induced overproduction of 
IL-10 was a dose-dependent phenomenon.  BMMφs were primed with increasing 
doses of recombinant IL-19 for 6 hours prior to stimulation.  IL-19 caused a dose-
dependent increase in IL-10 production in macrophages in response to stimulation 
with LPS/IC (Fig. 8A).  The effect was again specific to IL-10 production, since no 
similar dose-dependent effect was observed with either IL-12/23 p40 (Fig. 8B) or 
TNF-α (Fig. 8C). 
Priming with IL-19 increases IL-10 mRNA expression 
 We next wanted to know whether IL-19 regulated IL-10 at the level of mRNA 




























































































Fig. 7.  IL-19 priming enhances IL-10 production in regulatory macrophages. 
BMM φs were primed for 6 hours with either media or 100 pg/mL of recombinant IL-
19, then stimulated with either LPS or LPS/IC as indicated.  Supernatants were 
collected after 8 hours, the concentration of IL-10 and IL-12/23 p40 (A), and TNF-α 
(B) were measured by ELISA.  Data shown is representative of three separate 
















































































































































































Fig. 8.  IL-19 enhances IL-10 production in a dose-dependent manner. 
BMM φs were primed for 6 hours with increasing doses of recombinant IL-19, then 
stimulated with either LPS or LPS/IC as indicated.  Supernatants were collected after 
8 hours, the concentration of IL-10 (A), IL-12/23 p40 (B), and TNF-α (C) were 
measured by ELISA.  Data shown is representative of three separate experim nts.  




we primed BMMφs for 6 hours with increasing doses of recombinant IL-19.  After 4 
hours of stimulation with either LPS or LPS/IC, RNA was extracted and converted to 
cDNA.  PCR was then performed to detect total mRNA levels of IL-10, IL-12/23 
p40, and IL-19 (Fig. 9).  Surprisingly, IL-10 mRNA levels did not rise above that 
seen in the control sample.  In fact, IL-10 mRNA levels decreased in a dose-
dependent fashion with increased concentrations of IL-19, which is the exact opposite 
result of what was seen on the protein level measured by ELISA (Fig. 8A).  In 
addition, IL-19 induced IL-10 mRNA transcription in samples stimulated with LPS 
alone, although these levels did not increase with higher concentrations of IL-19.  I
19 also increased its own expression in cells stimulated with LPS, a fact that has lso 
been observed in human monocytes49.  This observation was also reversed in cells 
stimulated with LPS/IC, where IL-19 priming caused a decrease in IL-19 mRNA 
production in a dose-dependent manner.   
 We theorized that a possible explanation for the discrepancy between our 
observations at the protein and mRNA levels might be due to the fact that we were 
observing total mRNA product, and might instead need to look specifically at mature 
RNA being made in response to our experimental conditions.  The next step therefore 
was to use quantitative RT-PCR (QRT-PCR) to look for mature RNA transcript made 
in regulatory macrophages in response to IL-19 priming.  BMMφs were primed with 
either 100 pg/mL IL-19 or vehicle control (Fig. 10).  Cells were then stimulated wi h 
LPS/IC for the indicated time points.  RNA was then isolated and converted to 












Fig. 9. Effect of IL-19 priming on total mRNA expression. 
RT-PCR was performed to examine IL-10 expression in BMMφs primed with 
increasing concentrations of recombinant IL-19 for 6 hours.  Cells were stimulated 
with either LPS (left side) or LPS/IC (right side).  RNA was collected and reverse 
transcribed into cDNA, followed by PCR using primers specific for IL-10, IL-12/23 
p40, and IL-19.  GAPDH RNA was used as a loading control.  Data are representative 




                   
Stimulation Time (min.)






















IL-19 Primed (6hrs.) + IC/LPS
Stimulation Time (min.)
























IL-19 Primed (6hrs.) + IC/LPS
Stimulation Time (min.)

































Fig. 10.  Regulatory macrophages upregulate IL-10 mRNA in response to IL-19 
priming. 
(A) IL-10 mRNA was measured by QRT-PCR after priming with media plus vehicle 
control (closed circles) or with 100 pg/mL recombinant IL-19 (open circles), followed 
by stimulation with LPS plus immune complexes for the indicated time periods.  
QRT-PCR was also used to measure IL-12/23 p40 (B) and IL-19 (C) mRNA.  Fold 





specific for IL-10, IL-12/23 p40, and IL-19.  A robust increase in IL-10 mRNA levels 
was seen in regulatory macrophages primed with IL-19 compared to unprimed 
controls, with the peak expression appearing at 120 minutes post stimulation with 
LPS/IC (Fig. 10A).  This effect was not unique to IL-10, since IL-19 mRNA 
expression also increased in response to IL-19 priming in regulatory macrophages 
(Fig. 10C).  IL-12/23 p40 mRNA expression was not significantly affected (Fig. 
10B), indicating that IL-19 priming affects expression of only itself and IL-10.  This 
data is more in line with our previous experiments (Fig. 7, 8) and what has been 
reported in human monocytes49. 
IL-19 priming decreases ERK phosphorylation in regulatory macrophages 
 Since our lab has already established that IL-10 superinduction in regulatory 
macrophages is an ERK-dependent phenomenon 3, 32, 38, we theorized that IL-19 
priming would increase ERK activity in response to stimulation with LPS/IC.  To test 
this theory, BMMφs were cultured in the presence or absence of 100 pg/mL of 
recombinant IL-19 for 6 hrs.  Cells were then stimulated with either LPS or LPS/IC, 
then lysed and the protein analyzed by Western blotting.  Membranes were probed 
with antibodies specific for phosphorylated ERK, p38, and JNK (Fig. 11).  
Surprisingly, ERK phosphorylation was dramatically decreased in IL-19-primed 
macrophages that had been stimulated with LPS/IC as compared to cells stimulated 
with LPS/IC alone.  ERK phosphorylation peaked at only 5 minutes post stimulation, 
then decreased rapidly thereafter.  JNK and p38 activity remained the same in IL-19 


































Fig. 11.  ERK phosphorylation decreases in regulatory macrophages primed 
with IL-19. 
BMM φs were primed with either vehicle control (A) or 100 pg/mL of recombinant 
IL-19 for 6 hours (B), then stimulated with either LPS or LPS/IC as indicated.  Cells
were then lysed in the presence of protease and phosphotase inhibitors at the 
indicated time periods.  Samples were subjected to SDS-PAGE and Western blotting
with antibodies specific for phosphorylated ERK, p38 and JNK.  Antibodies specific 
for total ERK was used as a loading control.  Figures are representative of at l ast 
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specifically inhibits the robust ERK phosphorylation normally seen in regulatory 
macrophages while still producing a higher level of IL-10 then is seen with regulatory 
macrophages stimulated with LPS/IC alone (Fig. 8, 10). 
Discussion 
 We have shown here that IL-19 can upregulate IL-10 expression in regulatory 
macrophages in a dose-dependent manner, both at the mRNA and protein level.  
Strangely, this increase in IL-10 production did not seem to be dependent on ERK.  In 
fact, IL-19 significantly decreased ERK phosphorylation in cells stimulated with LPS 
plus immune complexes.  The fact that IL-19 priming did not cause this effect in cells 
stimulated with LPS alone indicates that signaling through the FcγR is still required 
for IL-10 production in these cells, but that an ERK-independent mechanism of 
activation may be involved.  Further studies should explore what the exact 
mechanism of IL-10 induction is in these cells.  In particular, studies should focus on 
the possibility that IL-19 priming increases access to the IL-10 promoter through an 
as-yet unknown ERK-independent pathway.  It would also be interesting to determent 
whether there are other differences in activity between regulatory macrophages and 
these same cells primed with IL-19, including whether or not the later cell typ  
expresses the same markers (e.g. LIGHT, HB-EGF), can bias T cells towards a Th2 
phenotype, or shows the same metabolic activity (e.g. arginine metabolism) as 
regulatory macrophages.  Further studies should also be made into the role of IL-19 in 
various murine models of disease, such as atherosclerosis and asthma, to determine 




Summary of Findings 
We have shown here that IL-19 is produced in classically activated, alternatively 
activated, and regulatory macrophages.  IL-19 is similar to IL-10 in that the quantity 
and kinetics of its production are increased in response to stimulation with LPS plus 
immune complexes as compared to stimulation with LPS alone.  Studies of the IL-19 
promoter, however, indicate that the major transcription factor(s) responsible for its 
production are located between 2 and 3 kb upstream from the transcription start site, 
and that LPS stimulation is sufficient to induce IL-19 production.  Furthermore, this 
LPS induced response is dependent on ERK activity, and partially dependent on p38 
activity.  IL-19 is also capable, in a dose-dependent manner, of increasing IL-10 
production in regulatory macrophages above the levels induced by stimulation with 
LPS/IC alone.  This is the case at both the level of IL-10 mRNA and protein.  In 
addition, ERK activity does not seem to play a significant role in IL-10 production as 
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